London
Roots Analysis has announced the addition of “RNAi Therapeutics
Market (2nd Edition), 2019-2030” report to its list
of offerings.
To order this 350+ page report, which features 130+ figures
and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key market Insights
Over
170 RNAi therapeutics are currently under development
Nearly 30% of
pipeline drugs are in the clinical phase, while the rest are either in the
preclinical / discovery stage. The majority of pipeline drug candidates are
delivered using siRNA conjugated delivery technology platform to mitigate
targeted delivery to organ / cell.
More than 70% of ongoing clinical trials are being
conducted in North America and Europe
In total, we came
across over 100 clinical trials that have been / are being conducted across the
globe. It is worth noting that around 40% of these trials were observed to be
phase II studies. Further, 75% of the active clinical trials being conducted in
this domain are evaluating siRNAs.
Over 36,000 patents were filed / granted related to RNAi
therapeutics since 2014
Majority of these
were patent applications (59%), followed by granted patents (40%). It is worth
highlighting that both industry and non-industry players are actively involved
in this domain. However, majority of the patents related to RNAi therapeutics
were filed / granted by industry players (58%).
USD
5.4+ billion invested by both private and public investors, since 2014
Around
USD 3 billion was raised through secondary offerings, representing more than
50% of the total capital raised by industry players till July 2019. Further,
there have been five instances of debt financing, accounting for more than USD
844 million in financing of RNAi therapeutics related initiatives.
Around
65 partnerships were inked since 2014
Maximum
number of deals were reported in 2018. Around 30% of the deals were related to
the R&D agreements; this was followed by technology licensing agreements
(27%).
RNAi
therapeutics market is anticipated to increase at a CAGR of over 45% between
2019-2030
This
growth is anticipated to be primarily driven by the target specificity of the
drug candidates. North America (primarily the US) are expected to capture the
majority share by 2030.
To request a sample
copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/278/request-sample.html
§ Who
are the leading industry players in this market?
§ What are the clinical conditions for which RNAi
therapeutics are being developed?
§ Who are the key investors in the RNAi therapeutics market?
§ What kind of commercialization strategies are being adopted
by RNAi therapeutics developers?
§ What are the different promotional and reimbursement
strategies used for RNAi therapeutics?
§ What are the prevalent R&D trends related to RNAi
therapeutics?
§ What are the various delivery / technology platforms that
are being used for the development of RNAi therapeutics?
§ What kind of partnership models are used by stakeholders in
this industry?
§ Who are the key service providers in this field of therapeutics?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
The USD 10 billion (by 2030) financial opportunity
within the RNAi therapeutics market has been analyzed across the following
segments:
§ Infectious diseases
§ Genetic disorders
§ Ophthalmic disorders
§ Hepatic disorders
§ Respiratory disorders
§ siRNA
§ miRNA
§ shRNA
§ sshRNA
§ DNA
§ Route of administration
§ Subcutaneous
§ Intravenous
§ Intradermal
§ Intratumoral
§ Intravitreal
§ Oral
§ Intramuscular
§ Key geographical regions
§ North America
§ Europe
§ Asia Pacific and the Rest of the World
§ Leading
Players
The
report features inputs from eminent industry stakeholder(s), according to whom
RNAi therapeutics are promising domain of pharmaceutical industry. The report
includes detailed transcripts of discussions held with the following expert(s):
§ Amotz Shemi (Chief Executive Officer, Silenseed)
The research covers
brief profiles, featuring an overview of the therapy, current development
status and clinical results. Each profile includes information on therapeutic
area, indication, targeted gene, route of administration, special designations,
mechanism of action, dosage, patent portfolio, technology portfolio, clinical
trials and recent developments (if available).
§ Alnylam Pharmaceuticals
§ Dicerna Pharmaceuticals
§ Souzhou Ribo Life Sciences
§ Olix Pharmaceuticals
§ Sirnaomics
§ Ariz Precision Medicine
§ Arrowhead Pharmaceuticals
§ Gradalis
§ Benitec Biopharma
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html or
email sales@rootsanalysis.com
You
may also be interested in the following titles:
1. Gene Therapy Market (3rdEdition), 2019-2030
2. Global T-Cell (CAR-T,
TCR and TIL) Therapy Market (4th Edition), 2019-2030
3. Biopharma Contract
Manufacturing Market (3rd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis